Novartis AG (NVSEF) stock
NVSEFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as NVS
$146.46+2.56 (+1.78%)
Close on Oct 19, 2026Market cap $279.46BP/E 20.5Yield –
Novartis r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $11.20B, up 11.8% from the year before. Over ten years it grew 2.3% a year on average. The highest annual figure on record is $11.37B in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.20B | +11.8% |
| FY2024 | Dec 31, 2024 | $10.02B | -11.9% |
| FY2023 | Dec 31, 2023 | $11.37B | +24.0% |
| FY2022 | Dec 31, 2022 | $9.17B | +6.1% |
| FY2021 | Dec 31, 2021 | $8.64B | -3.8% |
| FY2020 | Dec 31, 2020 | $8.98B | -4.5% |
| FY2019 | Dec 31, 2019 | $9.40B | +10.8% |
| FY2018 | Dec 31, 2018 | $8.49B | +1.2% |
| FY2017 | Dec 31, 2017 | $8.39B | -7.2% |
| FY2016 | Dec 31, 2016 | $9.04B | +1.2% |
| FY2015 | Dec 31, 2015 | $8.94B | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.85B | +14.0% |
| Q2 FY2025 | Jun 30, 2025 | $2.73B | +13.6% |
| Q2 FY2024 | Jun 30, 2024 | $2.37B | -3.0% |
| Q2 FY2023 | Jun 30, 2023 | $2.30B | +12.3% |
| Q2 FY2022 | Jun 30, 2022 | $2.50B | +17.5% |
| Q2 FY2021 | Jun 30, 2021 | $2.40B | +16.4% |
| Q2 FY2020 | Jun 30, 2020 | $2.44B | – |
| Q2 FY2019 | Jun 30, 2019 | $2.05B | – |
| Q2 FY2018 | Jun 30, 2018 | $2.13B | – |
| Q2 FY2017 | Jun 30, 2017 | $2.06B | – |
See a number that looks wrong?